Cordlife Group Limited (CLIFF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.91 Million SGD | -33.63% |
| 2022 | -11.16 Million USD | -18.17% |
| 2021 | -9.44 Million SGD | 55.99% |
| 2020 | -21.46 Million SGD | -53.39% |
| 2019 | -13.99 Million SGD | -121.75% |
| 2018 | -6.31 Million SGD | 15.23% |
| 2017 | -7.44 Million SGD | 58.76% |
| 2016 | -18.05 Million SGD | -319.0% |
| 2015 | 8.24 Million SGD | -90.2% |
| 2014 | 84.1 Million SGD | 524.92% |
| 2013 | -19.79 Million SGD | -1006.37% |
| 2012 | -1.78 Million SGD | 82.76% |
| 2011 | -10.37 Million SGD | -98.11% |
| 2010 | -5.23 Million SGD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | -12.61 Million SGD | 17.57% |
| 2023 Q2 | -8.05 Million USD | 36.19% |
| 2023 Q4 | -18 Million USD | -7.64% |
| 2023 FY | -14.91 Million SGD | -33.63% |
| 2023 Q3 | -16.73 Million SGD | -107.79% |
| 2022 Q1 | -13.14 Million SGD | -5.24% |
| 2022 FY | -11.16 Million USD | -18.17% |
| 2022 Q4 | -15.3 Million USD | -23.83% |
| 2022 Q3 | -12.36 Million SGD | -47.67% |
| 2022 Q2 | -8.37 Million SGD | 36.31% |
| 2021 Q1 | -18.43 Million SGD | -0.84% |
| 2021 Q3 | -14.61 Million SGD | 16.08% |
| 2021 Q4 | -12.49 Million SGD | 14.53% |
| 2021 FY | -9.44 Million SGD | 55.99% |
| 2021 Q2 | -17.41 Million SGD | 5.55% |
| 2020 Q2 | -14.72 Million SGD | 18.22% |
| 2020 Q3 | -19.86 Million SGD | -34.94% |
| 2020 Q4 | -18.28 Million SGD | 7.95% |
| 2020 FY | -21.46 Million SGD | -53.39% |
| 2020 Q1 | -18 Million SGD | -125.18% |
| 2019 Q4 | -7.99 Million SGD | 8.23% |
| 2019 Q1 | -7.78 Million SGD | -23.39% |
| 2019 FY | -13.99 Million SGD | -121.75% |
| 2019 Q2 | -17.35 Million SGD | -123.05% |
| 2019 Q3 | -8.71 Million SGD | 49.8% |
| 2018 Q2 | -7.44 Million SGD | -29.37% |
| 2018 FY | -6.31 Million SGD | 15.23% |
| 2018 Q4 | -6.3 Million SGD | -2.17% |
| 2018 Q3 | -6.17 Million SGD | 17.11% |
| 2018 Q1 | -5.75 Million SGD | 63.34% |
| 2017 Q4 | -15.69 Million SGD | -125.06% |
| 2017 FY | -7.44 Million SGD | 58.76% |
| 2017 Q3 | -6.97 Million SGD | 60.81% |
| 2017 Q2 | -17.79 Million SGD | -27.44% |
| 2017 Q1 | -13.96 Million SGD | 2.29% |
| 2016 Q4 | -14.29 Million SGD | -242.03% |
| 2016 FY | -18.05 Million SGD | -319.0% |
| 2016 Q3 | 10.06 Million SGD | 17.45% |
| 2016 Q2 | 8.56 Million SGD | 134.97% |
| 2016 Q1 | -24.49 Million SGD | 48.73% |
| 2015 FY | 8.24 Million SGD | -90.2% |
| 2015 Q4 | -47.78 Million SGD | -141.27% |
| 2015 Q3 | 115.77 Million SGD | 1.95% |
| 2015 Q2 | 113.56 Million SGD | 5.04% |
| 2015 Q1 | 108.11 Million SGD | 1.47% |
| 2014 Q1 | 5.15 Million SGD | 122.38% |
| 2014 Q4 | 106.54 Million SGD | 989.39% |
| 2014 Q3 | -11.98 Million SGD | 39.47% |
| 2014 Q2 | -19.79 Million SGD | -483.73% |
| 2014 FY | 84.1 Million SGD | 524.92% |
| 2013 Q3 | -2.03 Million SGD | -13.81% |
| 2013 Q4 | -23.04 Million SGD | -1031.83% |
| 2013 FY | -19.79 Million SGD | -1006.37% |
| 2013 Q1 | -1.74 Million SGD | -32.47% |
| 2013 Q2 | -1.78 Million SGD | -2.7% |
| 2012 Q1 | -31.65 Million SGD | 0.0% |
| 2012 FY | -1.78 Million SGD | 82.76% |
| 2012 Q2 | -10.37 Million SGD | 67.22% |
| 2012 Q4 | -1.31 Million SGD | 84.73% |
| 2012 Q3 | -8.61 Million SGD | 17.0% |
| 2011 Q2 | -5.23 Million SGD | 0.0% |
| 2011 FY | -10.37 Million SGD | -98.11% |
| 2010 FY | -5.23 Million SGD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 776.247% |
| Arrayit Corporation | 1.05 Million USD | 1513.251% |
| Atlantic International Corp. | 236.49 Thousand USD | 6407.929% |
| Biocept, Inc. | -788 Thousand USD | -1793.147% |
| Bioqual, Inc. | -12 Million USD | -24.243% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 65705.348% |
| DermTech, Inc. | 17.65 Million USD | 184.507% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 97.394% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | -102.226% |
| iMD Companies, Inc. | 1.11 Million USD | 1436.841% |
| IDenta Corp. | 524.85 Thousand USD | 2942.325% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 293.891% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -55250.252% |
| InVitro International | -313.14 Thousand USD | -4663.973% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 1052.67% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -2092186.115% |
| Medical Imaging Corp. | 3.79 Million USD | 493.518% |
| NovelStem International Corp. | 3.52 Million USD | 523.622% |
| Optigenex Inc. | 8.93 Million USD | 266.98% |
| PharmChem, Inc. | -1.49 Million USD | -898.251% |
| Proteome Sciences plc | 14.57 Million USD | 202.365% |
| Response Genetics, Inc | -13.08 Million USD | -14.0% |
| Rennova Health, Inc. | 14.82 Million USD | 200.594% |
| RushNet, Inc. | 4.8 Million USD | 410.737% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 11102.367% |
| Stella Diagnostics Inc. | 6.19 Million USD | 340.883% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 936.024% |
| Todos Medical Ltd. | 38.31 Million USD | 138.936% |